Literature DB >> 33156717

First Intraoperative Radiation Therapy Center in Africa: First 2 Years in Operation, Including COVID-19 Experiences.

Yastira Ramdas1, Carol-Ann Benn1, Michelle van Heerden2.   

Abstract

PURPOSE: There is a shortage of radiation therapy service centers in low- to middle-income countries. TARGIT-intraoperative radiation therapy (IORT) may offer a viable alternative to improve radiation treatment efficiency and alleviate hospital patient loads. The Breast Care Unit in Johannesburg became the first facility in Africa to offer TARGIT-IORT, and the purpose of this study was to present a retrospective review of patients receiving IORT at this center between November 2017 and May 2020. PATIENTS AND METHODS: Patient selection criteria were based mainly on the latest American Society of Radiation Oncology guidelines. Selection criteria included early-stage breast carcinoma (luminal A) and luminal B with negative upfront sentinel lymph node biopsy that negated external-beam radiation therapy (EBRT). Patient characteristics, reasons for choosing IORT, histology, and use of oncoplastic surgery that resulted in complications were recorded.
RESULTS: One hundred seven patients successfully received IORT/TARGIT-IORT. Mean age was 60.8 years (standard deviation, 9.3 years). A total of 73.8% of patients presented with luminal A, 15.0% with luminal B, and 5.6% with triple-negative cancer. One patient who presented with locally advanced breast cancer (T4N2) opted for IORT as a boost in addition to planned EBRT. Eighty-seven patients underwent wide local excision (WLE) with mastopexy, and 12 underwent WLE with parenchymal. Primary reasons for selecting IORT/TARGIT-IORT were distance from the hospital (43.9%), choice (40.2%), and age (10.3%).
CONCLUSION: This retrospective study of IORT/TARGIT-IORT performed in Africa confirms its viability, with low complication rates and no detrimental effects with breast conservation, resulting in positive acceptance and the potential to reduce Oncology Center patient loads. Limitations of the study include the fact that only short-term data on local recurrence were available. Health and socioeconomic value models must still be addressed in the African setting.

Entities:  

Mesh:

Year:  2020        PMID: 33156717      PMCID: PMC7713533          DOI: 10.1200/GO.20.00258

Source DB:  PubMed          Journal:  JCO Glob Oncol        ISSN: 2687-8941


  31 in total

1.  Dosimetric characteristics of a low-kV intra-operative x-ray source: implications for use in a clinical trial for treatment of low-risk breast cancer.

Authors:  M A Ebert; B Carruthers
Journal:  Med Phys       Date:  2003-09       Impact factor: 4.071

2.  Multicentricity and recurrence of breast cancer.

Authors:  P J Drew; L W Turnbull; M J Kerin; P J Carleton; J N Fox
Journal:  Lancet       Date:  1997-01-18       Impact factor: 79.321

Review 3.  History, preliminary results, complications, and future prospects of intraoperative radiotherapy.

Authors:  H J Hoekstra; W F Sindelar; T J Kinsella; J Oldhoff
Journal:  J Surg Oncol       Date:  1987-11       Impact factor: 3.454

4.  Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Armando E Giuliano; James L Connolly; Stephen B Edge; Elizabeth A Mittendorf; Hope S Rugo; Lawrence J Solin; Donald L Weaver; David J Winchester; Gabriel N Hortobagyi
Journal:  CA Cancer J Clin       Date:  2017-03-14       Impact factor: 508.702

5.  Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery.

Authors:  Jayant S Vaidya; Michael Baum; Jeffrey S Tobias; Frederik Wenz; Samuele Massarut; Mohammed Keshtgar; Basil Hilaris; Christobel Saunders; Norman R Williams; Chris Brew-Graves; Tammy Corica; Mario Roncadin; Uta Kraus-Tiefenbacher; Marc Sütterlin; Max Bulsara; David Joseph
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-15       Impact factor: 7.038

Review 6.  Boost IORT in Breast Cancer: Body of Evidence.

Authors:  Felix Sedlmayer; Roland Reitsamer; Christoph Fussl; Ingrid Ziegler; Franz Zehentmayr; Heinz Deutschmann; Peter Kopp; Gerd Fastner
Journal:  Int J Breast Cancer       Date:  2014-09-02

Review 7.  Intraoperative Radiotherapy for Breast Cancer.

Authors:  Eleanor E R Harris; William Small
Journal:  Front Oncol       Date:  2017-12-22       Impact factor: 6.244

8.  The outbreak of COVID-19: An overview.

Authors:  Yi-Chi Wu; Ching-Sung Chen; Yu-Jiun Chan
Journal:  J Chin Med Assoc       Date:  2020-03       Impact factor: 2.743

9.  Multicentricity of breast cancer: whole-organ analysis and clinical implications.

Authors:  J S Vaidya; J J Vyas; R F Chinoy; N Merchant; O P Sharma; I Mittra
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

10.  A War on Two Fronts: Cancer Care in the Time of COVID-19.

Authors:  Alexander Kutikov; David S Weinberg; Martin J Edelman; Eric M Horwitz; Robert G Uzzo; Richard I Fisher
Journal:  Ann Intern Med       Date:  2020-03-27       Impact factor: 25.391

View more
  1 in total

1.  Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer-better for patients, better for healthcare systems.

Authors:  Jayant Sharad Vaidya; Uma Jayant Vaidya; Michael Baum; Max Kishor Bulsara; David Joseph; Jeffrey S Tobias
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.